Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Summary by Relevant Sections Allegations - The complaint claims that Centene's management made overly positive statements while concealing adverse facts about the company's true enrollment and morbidity rates [3]. - On July 1, 2025, Centene announced a withdrawal of its 2025 guidance, revealing that its market growth across 22 states was lower than expected, affecting 72% of its marketplace membership [3]. - The revised guidance indicated a reduction to approximately $1.8 billion in revenue and an adjusted diluted EPS of $2.75 [3]. Stock Performance - Following the announcement on July 1, 2025, Centene's stock price plummeted from $56.65 per share to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Class Action Details - The class period for the lawsuit is defined as December 12, 2024, to June 30, 2025 [3]. - Shareholders are encouraged to register for the class action by September 8, 2025, to potentially be appointed as lead plaintiffs [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Information - The Gross Law Firm is leading the class action and is recognized for protecting investors' rights against deceit and fraud [5].
The Gross Law Firm Reminds Centene Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 8, 2025 – CNC